130 related articles for article (PubMed ID: 17139573)
1. Drug evaluation: the directly activated Factor Xa inhibitor otamixaban.
Nutescu EA; Pater K
IDrugs; 2006 Dec; 9(12):854-65. PubMed ID: 17139573
[TBL] [Abstract][Full Text] [Related]
2. Direct and rapid inhibition of factor Xa by otamixaban: a pharmacokinetic and pharmacodynamic investigation in patients with coronary artery disease.
Hinder M; Frick A; Jordaan P; Hesse G; Gebauer A; Maas J; Paccaly A
Clin Pharmacol Ther; 2006 Dec; 80(6):691-702. PubMed ID: 17178269
[TBL] [Abstract][Full Text] [Related]
3. Pharmacodynamic markers in the early clinical assessment of otamixaban, a direct factor Xa inhibitor.
Paccaly A; Ozoux ML; Chu V; Simcox K; Marks V; Freyburger G; Sibille M; Shukla U
Thromb Haemost; 2005 Dec; 94(6):1156-63. PubMed ID: 16411387
[TBL] [Abstract][Full Text] [Related]
4. Randomized, double-blind, dose-ranging study of otamixaban, a novel, parenteral, short-acting direct factor Xa inhibitor, in percutaneous coronary intervention: the SEPIA-PCI trial.
Cohen M; Bhatt DL; Alexander JH; Montalescot G; Bode C; Henry T; Tamby JF; Saaiman J; Simek S; De Swart J;
Circulation; 2007 May; 115(20):2642-51. PubMed ID: 17502577
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of otamixaban, a direct factor Xa inhibitor, in healthy male subjects: pharmacokinetic model development for phase 2/3 simulation of exposure.
Paccaly A; Frick A; Rohatagi S; Liu J; Shukla U; Rosenburg R; Hinder M; Jensen BK
J Clin Pharmacol; 2006 Jan; 46(1):37-44. PubMed ID: 16397282
[TBL] [Abstract][Full Text] [Related]
6. Otamixaban for the treatment of patients with non-ST-elevation acute coronary syndromes (SEPIA-ACS1 TIMI 42): a randomised, double-blind, active-controlled, phase 2 trial.
Sabatine MS; Antman EM; Widimsky P; Ebrahim IO; Kiss RG; Saaiman A; Polasek R; Contant CF; McCabe CH; Braunwald E
Lancet; 2009 Sep; 374(9692):787-95. PubMed ID: 19717184
[TBL] [Abstract][Full Text] [Related]
7. The discovery of the Factor Xa inhibitor otamixaban: from lead identification to clinical development.
Guertin KR; Choi YM
Curr Med Chem; 2007; 14(23):2471-81. PubMed ID: 17979700
[TBL] [Abstract][Full Text] [Related]
8. Otamixaban in acute coronary syndromes.
Eikelboom JW; Weitz JI
Lancet; 2009 Sep; 374(9692):762-4. PubMed ID: 19717186
[No Abstract] [Full Text] [Related]
9. Pharmacokinetic/pharmacodynamic relationships for otamixaban, a direct factor Xa inhibitor, in healthy subjects.
Paccaly A; Frick A; Ozoux ML; Chu V; Rosenburg R; Hinder M; Shukla U; Jensen BK
J Clin Pharmacol; 2006 Jan; 46(1):45-51. PubMed ID: 16397283
[TBL] [Abstract][Full Text] [Related]
10. Anticoagulant and anti-platelet effects are maintained following coadministration of otamixaban, a direct factor Xa inhibitor, and acetylsalicylic acid.
Hinder M; Frick A; Rosenburg R; Hesse G; Ozoux ML; Laux V; Scholtz H; Gebauer A; Paccaly A
Thromb Haemost; 2006 Feb; 95(2):224-8. PubMed ID: 16493482
[TBL] [Abstract][Full Text] [Related]
11. Large inter-individual variation of the pharmacodynamic effect of anticoagulant drugs on thrombin generation.
Bloemen S; Hemker HC; Al Dieri R
Haematologica; 2013 Apr; 98(4):549-54. PubMed ID: 23100275
[TBL] [Abstract][Full Text] [Related]
12. [Factor Xa-inhibition in interventional cardiology].
Ahrens I; Peter K; Bode C
Hamostaseologie; 2007 Dec; 27(5):328-32. PubMed ID: 18060241
[TBL] [Abstract][Full Text] [Related]
13. Preclinical and clinical characteristics of rivaroxaban: a novel, oral, direct factor Xa inhibitor.
Laux V; Perzborn E; Kubitza D; Misselwitz F
Semin Thromb Hemost; 2007 Jul; 33(5):515-23. PubMed ID: 17629849
[TBL] [Abstract][Full Text] [Related]
14. Rivaroxaban: a novel, oral, direct factor Xa inhibitor.
Abrams PJ; Emerson CR
Pharmacotherapy; 2009 Feb; 29(2):167-81. PubMed ID: 19170587
[TBL] [Abstract][Full Text] [Related]
15. Survival of heparins, oral anticoagulants, and aspirin after the year 2010.
Fareed J; Hoppensteadt DA; Fareed D; Demir M; Wahi R; Clarke M; Adiguzel C; Bick R
Semin Thromb Hemost; 2008 Feb; 34(1):58-73. PubMed ID: 18393143
[TBL] [Abstract][Full Text] [Related]
16. Design, synthesis, and biological activity of non-amidine factor Xa inhibitors containing pyridine N-oxide and 2-carbamoylthiazole units.
Haginoya N; Kobayashi S; Komoriya S; Yoshino T; Nagata T; Hirokawa Y; Nagahara T
Bioorg Med Chem; 2004 Nov; 12(21):5579-86. PubMed ID: 15465335
[TBL] [Abstract][Full Text] [Related]
17. Potent arterial antithrombotic effect of direct factor-Xa inhibition with ZK-807834 administered to coronary artery disease patients.
Zafar MU; Farkouh ME; Osende J; Shimbo D; Palencia S; Crook J; Leadley R; Fuster V; Chesebro JH
Thromb Haemost; 2007 Mar; 97(3):487-92. PubMed ID: 17334518
[TBL] [Abstract][Full Text] [Related]
18. DU-176b, an oral, direct Factor Xa antagonist.
Hylek E
Curr Opin Investig Drugs; 2007 Sep; 8(9):778-83. PubMed ID: 17729190
[TBL] [Abstract][Full Text] [Related]
19. Is there evidence to support the use of direct Factor Xa inhibitors in coronary artery disease?
Doggrell SA
Rev Recent Clin Trials; 2011 May; 6(2):147-57. PubMed ID: 21241235
[TBL] [Abstract][Full Text] [Related]
20. DX-9065a Daiichi.
Kaiser B
Curr Opin Investig Drugs; 2003 Sep; 4(9):1105-12. PubMed ID: 14582456
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
